NDC11 65757065444
This exact 11-digit normalized identifier can correspond to more than one FDA hyphenation. FDA.report preserves the exact identifier and exposes every structurally valid candidate without guessing.
Possible FDA NDC forms#
| Package NDC | Product root |
|---|---|
| 65757-0654-44 | 65757-0654 |
| 65757-654-44 | 65757-654 |
NDC auxiliary status#
These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| excluded package | package | 65757-654 | 65757-654-44 | D | Discontinued by firm | 2026-08-17 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| LYBALVI | OLANZAPINE AND SAMIDORPHAN L-MALATE | Alkermes, Inc. | 32ffddd1-4e2b-45d9-9b36-bb730167ec80 | 2026-01-31 | Boxed warning, Warnings, Adverse reactions | 65757-654-44 65757-654 65757065444 |